{
  "title": "HYVET (2008) Hypertension in the Very Elderly Trial  ‚≠ê Estudio pivote HTA en ‚â•80 a√±os",
  "guid": "HYVET-2008-STUDY",
  "filepath": "/sessions/bold-jolly-cerf/mnt/Dropbox/- Esquemas/- Estudios Pivotales/HYVET-2026.smmx",
  "root": {
    "id": "0",
    "parent": "-1",
    "text": "HYVET (2008)\nHypertension in the Very Elderly Trial\n\n‚≠ê Estudio pivote HTA en ‚â•80 a√±os",
    "guid": "HYVET-ROOT",
    "children": [
      {
        "id": "1",
        "parent": "0",
        "text": "üìã IDENTIFICACI√ìN",
        "guid": "HYVET-ID",
        "children": [
          {
            "id": "2",
            "parent": "1",
            "text": "Acr√≥nimo\nHYpertension in the Very Elderly Trial",
            "guid": "HYVET-ID1",
            "children": []
          },
          {
            "id": "3",
            "parent": "1",
            "text": "Publicaci√≥n\nNEJM 2008;358:1887-98\nDOI: 10.1056/NEJMoa0801369",
            "guid": "HYVET-ID2",
            "children": []
          },
          {
            "id": "4",
            "parent": "1",
            "text": "Financiamiento\nBritish Heart Foundation",
            "guid": "HYVET-ID3",
            "children": []
          }
        ]
      },
      {
        "id": "5",
        "parent": "0",
        "text": "üî¨ DISE√ëO",
        "guid": "HYVET-DESIGN",
        "children": [
          {
            "id": "6",
            "parent": "5",
            "text": "Tipo\nRCT doble ciego\nPlacebo-controlado",
            "guid": "HYVET-D1",
            "children": []
          },
          {
            "id": "7",
            "parent": "5",
            "text": "Pa√≠ses\n195 centros, 13 pa√≠ses\n(Europa, China, Australasia)",
            "guid": "HYVET-D2",
            "children": []
          },
          {
            "id": "8",
            "parent": "5",
            "text": "Per√≠odo\n2001-2007\nSeguimiento: 1.8 a√±os\nTerminado precozmente",
            "guid": "HYVET-D3",
            "children": []
          }
        ]
      },
      {
        "id": "9",
        "parent": "0",
        "text": "üë• POBLACI√ìN",
        "guid": "HYVET-POP",
        "children": [
          {
            "id": "10",
            "parent": "9",
            "text": "n = 3845 aleatorizados\n1933 indapamida\n1912 placebo",
            "guid": "HYVET-P1",
            "children": []
          },
          {
            "id": "11",
            "parent": "9",
            "text": "Criterios inclusi√≥n\n‚Ä¢ Edad ‚â•80 a√±os\n‚Ä¢ PAS 160-199 mmHg\n‚Ä¢ PAD menor a 110 mmHg",
            "guid": "HYVET-P2",
            "children": []
          },
          {
            "id": "12",
            "parent": "9",
            "text": "Exclusi√≥n\n‚Ä¢ HTA secundaria\n‚Ä¢ IC que requiere antiHTA\n‚Ä¢ Demencia\n‚Ä¢ Dependencia",
            "guid": "HYVET-P3",
            "children": []
          },
          {
            "id": "13",
            "parent": "9",
            "text": "Edad media: 83.6 a√±os\n60.5% mujeres\nPA: 173/90 mmHg",
            "guid": "HYVET-P4",
            "children": []
          }
        ]
      },
      {
        "id": "14",
        "parent": "0",
        "text": "üíä INTERVENCI√ìN",
        "guid": "HYVET-INT",
        "children": [
          {
            "id": "15",
            "parent": "14",
            "text": "Grupo activo\nIndapamida SR 1.5 mg/d√≠a\n¬± Perindopril 2-4 mg",
            "guid": "HYVET-I1",
            "children": []
          },
          {
            "id": "16",
            "parent": "14",
            "text": "Meta: PA menor a 150/80 mmHg",
            "guid": "HYVET-I2",
            "children": []
          }
        ]
      },
      {
        "id": "17",
        "parent": "0",
        "text": "üìä OUTCOMES",
        "guid": "HYVET-OUT",
        "children": [
          {
            "id": "18",
            "parent": "17",
            "text": "Outcome primario\nACV fatal o no fatal\nHR 0.70 (0.49-1.01) p=0.06\n‚Üì30% (no significativo)",
            "guid": "HYVET-O1",
            "children": []
          },
          {
            "id": "19",
            "parent": "17",
            "text": "Outcomes secundarios ‚≠ê\n‚Ä¢ Mortalidad total: ‚Üì21% p=0.02\n‚Ä¢ IC: ‚Üì64% p menor a 0.001\n‚Ä¢ ACV fatal: ‚Üì39%",
            "guid": "HYVET-O2",
            "children": []
          },
          {
            "id": "20",
            "parent": "17",
            "text": "NNT\n‚Ä¢ ACV: 40 a 2 a√±os\n‚Ä¢ Mortalidad: 40 a 2 a√±os",
            "guid": "HYVET-O3",
            "children": []
          }
        ]
      },
      {
        "id": "21",
        "parent": "0",
        "text": "‚ö†Ô∏è SESGOS",
        "guid": "HYVET-SEG",
        "children": [
          {
            "id": "22",
            "parent": "21",
            "text": "Limitaciones\n‚Ä¢ Terminado precozmente\n‚Ä¢ Run-in period\n‚Ä¢ Excluye dementes/fr√°giles\n‚Ä¢ Seguimiento corto",
            "guid": "HYVET-S1",
            "children": []
          },
          {
            "id": "23",
            "parent": "21",
            "text": "Sesgo selecci√≥n\nNo aplica a poblaci√≥n\ngeri√°trica real (fr√°giles)",
            "guid": "HYVET-S2",
            "children": []
          }
        ]
      },
      {
        "id": "24",
        "parent": "0",
        "text": "üè• GERIATR√çA",
        "guid": "HYVET-GER",
        "children": [
          {
            "id": "25",
            "parent": "24",
            "text": "Fortalezas\n‚Ä¢ √önico RCT en ‚â•80 a√±os\n‚Ä¢ Meta conservadora 150/80",
            "guid": "HYVET-G1",
            "children": []
          },
          {
            "id": "26",
            "parent": "24",
            "text": "Precauciones\n‚Ä¢ No aplica a fr√°giles\n‚Ä¢ Vigilar hipotensi√≥n ortost√°tica\n‚Ä¢ Evaluar expectativa vida",
            "guid": "HYVET-G2",
            "children": []
          }
        ]
      },
      {
        "id": "27",
        "parent": "0",
        "text": "üíé PERLAS CL√çNICAS",
        "guid": "HYVET-PERLAS",
        "children": [
          {
            "id": "28",
            "parent": "27",
            "text": "1. Primer RCT que demuestra\nbeneficio tratar HTA en ‚â•80",
            "guid": "HYVET-PE1",
            "children": []
          },
          {
            "id": "29",
            "parent": "27",
            "text": "2. Meta 150/80 es razonable\nen muy ancianos",
            "guid": "HYVET-PE2",
            "children": []
          },
          {
            "id": "30",
            "parent": "27",
            "text": "3. ‚ÜìIC 64% inesperado",
            "guid": "HYVET-PE3",
            "children": []
          },
          {
            "id": "31",
            "parent": "27",
            "text": "4. NO aplica a fr√°giles/dementes",
            "guid": "HYVET-PE4",
            "children": []
          }
        ]
      },
      {
        "id": "32",
        "parent": "0",
        "text": "üìö Referencias",
        "guid": "HYVET-REF",
        "children": [
          {
            "id": "33",
            "parent": "32",
            "text": "1. Beckett NS, et al. NEJM 2008\n2. Peters R, Lancet Neurol 2008",
            "guid": "HYVET-R1",
            "children": []
          }
        ]
      }
    ]
  },
  "node_count": 34,
  "relations": [],
  "cross_references": [],
  "specialty": "Geriatr√≠a",
  "folder": "- Estudios Pivotales",
  "filename": "HYVET-2026",
  "id": "map_17",
  "resolved_references": []
}